Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 8 studies | 23% ± 9% | |
mature NK T cell | 7 studies | 22% ± 7% | |
B cell | 6 studies | 23% ± 3% | |
CD8-positive, alpha-beta T cell | 6 studies | 25% ± 12% | |
gamma-delta T cell | 6 studies | 21% ± 4% | |
CD16-positive, CD56-dim natural killer cell, human | 5 studies | 23% ± 5% | |
effector memory CD8-positive, alpha-beta T cell | 5 studies | 28% ± 9% | |
endothelial cell of artery | 5 studies | 18% ± 3% | |
mucosal invariant T cell | 5 studies | 19% ± 2% | |
platelet | 4 studies | 18% ± 1% | |
CD8-positive, alpha-beta memory T cell | 4 studies | 23% ± 3% | |
effector memory CD4-positive, alpha-beta T cell | 4 studies | 24% ± 8% | |
T cell | 3 studies | 20% ± 3% | |
naive B cell | 3 studies | 20% ± 4% | |
naive thymus-derived CD4-positive, alpha-beta T cell | 3 studies | 21% ± 3% | |
naive thymus-derived CD8-positive, alpha-beta T cell | 3 studies | 24% ± 5% | |
CD4-positive, alpha-beta T cell | 3 studies | 23% ± 10% | |
classical monocyte | 3 studies | 29% ± 7% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 4 studies | 27% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
skin | 100% | 3440.41 | 1809 / 1809 | 100% | 68.86 | 471 / 472 |
stomach | 100% | 990.02 | 359 / 359 | 100% | 55.06 | 285 / 286 |
esophagus | 100% | 882.63 | 1439 / 1445 | 100% | 55.97 | 183 / 183 |
thymus | 100% | 1160.26 | 652 / 653 | 100% | 43.14 | 603 / 605 |
intestine | 100% | 1133.19 | 966 / 966 | 99% | 48.10 | 523 / 527 |
uterus | 99% | 803.22 | 169 / 170 | 100% | 51.64 | 457 / 459 |
lung | 100% | 1656.18 | 577 / 578 | 99% | 45.02 | 1143 / 1155 |
breast | 100% | 1167.73 | 459 / 459 | 98% | 43.08 | 1098 / 1118 |
bladder | 100% | 1167.33 | 21 / 21 | 97% | 42.05 | 489 / 504 |
ovary | 97% | 659.84 | 174 / 180 | 100% | 53.22 | 430 / 430 |
kidney | 98% | 886.90 | 87 / 89 | 98% | 29.77 | 886 / 901 |
prostate | 98% | 693.36 | 239 / 245 | 98% | 26.38 | 493 / 502 |
liver | 97% | 665.76 | 219 / 226 | 98% | 30.51 | 398 / 406 |
pancreas | 87% | 430.96 | 284 / 328 | 98% | 38.93 | 175 / 178 |
adrenal gland | 90% | 513.71 | 233 / 258 | 71% | 15.11 | 163 / 230 |
brain | 48% | 214.81 | 1272 / 2642 | 97% | 22.82 | 684 / 705 |
eye | 0% | 0 | 0 / 0 | 100% | 93.49 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 115.13 | 29 / 29 |
spleen | 100% | 2347.56 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 55.18 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 23.32 | 1 / 1 |
adipose | 100% | 1117.54 | 1202 / 1204 | 0% | 0 | 0 / 0 |
muscle | 100% | 1647.68 | 799 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 2925.90 | 922 / 929 | 0% | 0 | 0 / 0 |
heart | 88% | 477.99 | 761 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 77% | 471.10 | 1029 / 1335 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0045762 | Biological process | positive regulation of adenylate cyclase activity |
GO_0007200 | Biological process | phospholipase C-activating G protein-coupled receptor signaling pathway |
GO_0051924 | Biological process | regulation of calcium ion transport |
GO_0002115 | Biological process | store-operated calcium entry |
GO_1990806 | Biological process | ligand-gated ion channel signaling pathway |
GO_0032024 | Biological process | positive regulation of insulin secretion |
GO_0002250 | Biological process | adaptive immune response |
GO_0070509 | Biological process | calcium ion import |
GO_0061180 | Biological process | mammary gland epithelium development |
GO_0051928 | Biological process | positive regulation of calcium ion transport |
GO_0070588 | Biological process | calcium ion transmembrane transport |
GO_0099105 | Biological process | ion channel modulating, G protein-coupled receptor signaling pathway |
GO_0005886 | Cellular component | plasma membrane |
GO_0045121 | Cellular component | membrane raft |
GO_0016020 | Cellular component | membrane |
GO_0044853 | Cellular component | plasma membrane raft |
GO_0034704 | Cellular component | calcium channel complex |
GO_0016323 | Cellular component | basolateral plasma membrane |
GO_0042802 | Molecular function | identical protein binding |
GO_0015279 | Molecular function | store-operated calcium channel activity |
GO_0005516 | Molecular function | calmodulin binding |
GO_0005515 | Molecular function | protein binding |
GO_0005262 | Molecular function | calcium channel activity |
Gene name | ORAI1 |
Protein name | Calcium release-activated calcium channel protein 1 (Protein orai-1) (Transmembrane protein 142A) |
Synonyms | TMEM142A CRACM1 |
Description | FUNCTION: Ca(2+) release-activated Ca(2+) (CRAC) channel subunit which mediates Ca(2+) influx following depletion of intracellular Ca(2+) stores and channel activation by the Ca(2+) sensor, STIM1 . CRAC channels are the main pathway for Ca(2+) influx in T-cells and promote the immune response to pathogens by activating the transcription factor NFAT . Plays a prominent role in Ca(2+) influx at the basolateral membrane of mammary epithelial cells independently of the Ca(2+) content of endoplasmic reticulum or Golgi stores. May mediate transepithelial transport of large quantities of Ca(2+) for milk secretion. . |
Accessions | ENST00000617316.2 [Q96D31-1] Q96D31 |